ABSTRACT Interventions aimed at reducing sexual transmission of human immunodeficiency virus/sexually transmitted diseases (HIV/STDs
INTRODUCTION
Reduction of unprotected sexual activity prevents the transmission of human immunodeficiency virus (HIV) to the uninfected, as well as HIV reinfection among HIVpositive individuals. As a group, women have sustained the largest increases in rates of new HIV infections and diagnoses of acquired immunodeficiency syndrome (AIDS) of all at-risk populations in the US, and minority women are disproportionately represented among HIV/AIDS cases. 1 The rapid increase in heterosexual transmission, since 1995 the primary mode of infection among women, 1, 2 highlights the importance of effective interventions that reduce sexual risk behavior, particularly among minority women who are HIV positive. Most minority women living with HIV/AIDS are poor, between the ages of 18 and 40 years, and at significant risk of exposure to other treatable sexually transmitted diseases (STDs). 2, 3 STDs are associated with increased risk for HIV infection or reinfection, 4, 5 increased HIV viral load, 2, 3 pelvic inflammatory disease, ectopic pregnancy, or chronic pelvic pain. 2, 6, 7 In addition, for women living with HIV, bacterial vaginosis infection increases the risk of STD infection and the transmission of HIV from pregnant women to infants. 2 At the onset of the HIV/AIDS pandemic, safer sex interventions designed to restrict transmission of HIV and other STDs primarily relied on promoting abstinence or increasing condom use by the uninfected. Later approaches included hierarchical interventions (e.g., New York State Department of Health AIDS Institute's Hierarchical Method of Prevention), [8] [9] [10] [11] which presented a ranking of sexual protection methods from the safest, male and female condoms, to the most risky, spermicides based on nonoxynol-9. Most evaluations of hierarchical approaches have found that male condom use continues, and the overall proportional rates of protected sex acts was significantly increased following intervention. [10] [11] [12] However, most hierarchical interventions have not evaluated these findings beyond 6 months.
Many women living with HIV continue to practice HIV-risky sexual behavior, 12,13 often associated with relationship status, poverty, emotional status, substance abuse, and personality factors. [13] [14] [15] [16] Among HIV-positive people, risk behavior may also be influenced by the perception of lessened infectivity due to medication and reduced viral load. 14 Results from prevention studies have emphasized the importance of tailoring interventions to address the needs, beliefs, and values of specific target populations, 17, 18 such as HIV-positive women. 2 HIV-positive women have generally been neglected in social science intervention research in comparison to other populations. Yet, interventions targeting HIV-positive women contribute to both primary and secondary prevention by providing strategies for reduction of transmission and prevention of HIV reinfection and other STD infections, respectively.
Acceptability studies have assessed women's preferences regarding specific characteristics of female-controlled chemical barrier products (microbicides) 19, 20 in anticipation of the eventual availability of a safe and effective vaginally applied method of protection against HIV/STD transmission. Research suggests that use of chemical barriers is better predicted by knowledge of appropriate use, rather than fear of HIV/AIDS transmission risk, and that exposure to such products is essential to effecting behavior change. 15 Despite the ready availability of N-9-based spermicides (marketed as a spermicidal contraceptive), little information exists on the acceptability of such products among seropositive women. This may be due, in part, to the circumstances of use of some forms of N-9, which has been associated with vaginal irritation 22 and lesion-based HIV shedding, 23 either of which may increase risk of STD/HIV transmission.
This pilot study tested a culturally sensitive physical and chemical sexual barrier intervention designed to assess the acceptability following use of potential adjuncts or, for some women, alternatives to male and female condoms in the form of N-9 spermicidal barriers. We hoped to identify what prevented, as well as promoted, future willingness to use sexual barriers among HIV-positive women and the role of cultural considerations as impediments to use.
METHODS

Recruitment and Eligibility
Participants in the pilot sexual behavioral intervention were drawn from the SMART/EST Women's Project, a multisite phase III clinical trial; internal review board approval was obtained prior to the onset of the study. From 1997 to 1999, the SMART/EST Women's Project recruited from three major epicenters in the US for women living with HIV/AIDS: Miami-Dade County, Florida; New York City; and the New Jersey metropolitan area. Study candidates were drawn primarily from hospitals and community health centers/agencies and via participant referrals. SMART/EST Women participants (n = 465) were 18 years of age or older and met the Centers for Disease Control and Prevention (CDC) guidelines for case-defined AIDS (i.e., CD4 cell count below 200/mm 3 and/or one opportunistic infection).
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The pilot sexual barrier intervention was introduced in the SMART/EST Women's Project in mid-1998. Following its introduction, 89 of the women were enrolled in the pilot intervention, and these women were matched with 89 women previously enrolled in the control arm of the SMART/EST Project (intervention condition = 89, control condition = 89). Interested candidates were initially screened by telephone to determine potential eligibility (see the Figure) . Candidates who were deemed eligible (age ≥ 18 years and clinical AIDS diagnosis as described above) completed an informed consent form and were assessed with the Mini-Mental State Exam, 24 the HIV Dementia Scale, 25 the Structured Clinical Interview for DSM-III-R, Nonpatient Version for HIV Studies (SCID-NP-HIV), 26 and the Karnofsky ADL Scale 27 (score > 60, able to provide self-care) to confirm eligibility for the SMART/EST Project. Participants then completed psychosocial questionnaires.
Participants completed a sexual barrier intervention baseline assessment. All control condition participants were enrolled prior to the onset of the sexual barrier intervention and completed three monthly control condition discussion sessions. All sexual barrier intervention participants completed three monthly intervention condition sessions over 3 months. Participants were followed over a 12-month period (baseline assessment, 3-and 9-month postintervention follow-up). All participants received monetary compensation for their time and travel expenses. Study assessors and investigators were blind to participant condition assignment and did not participate in provision of the intervention. Participants were asked not to reveal their condition assignment to assessors.
Due to the provision of vaginal products, all intervention participants were screened for STDs and vaginal abnormalities prior to receiving N-9 spermicides. If contraindications for N-9 use (discharge, burning, itching, or lesions) were identi- fied, participants received product information, but were only provided with male and female condoms. Women referred for treatment and cleared for use were then provided with N-9 spermicides. Women were notified of their STD results, were advised as to appropriate treatment, and were referred for follow-up. Barrier intervention participants were matched with previously enrolled non-barrier intervention participants on age and/or ethnicity (n = 89, see the Figure; N = 178 participants in all).
Sexual Barrier Intervention
The sexual barrier intervention was manualized and developed with feedback from previous pilot participants. Facilitators were psychologists trained in the administration of the intervention. Each of the 120-minute sessions provided an opportunity for practice, feedback, and reinforcement in a supportive environment. 12, [28] [29] [30] Sessions addressed HIV/STD transmission, hierarchical counseling, and skill training to facilitate product use. Discussion focused on reactions to barriers, cognitive reframing, and sexual negotiation.
Information was presented through multiple modalities (i.e., written handouts, videos, hands-on experience). The intervention and accompanying videos were developed in English, Spanish, and Creole languages and culturally tailored to each audience (African American, Hispanic, Haitian); all sessions were held in English, Spanish, and Creole by linguistically matched facilitators. Videos were created specifically for HIV-positive women and illustrated the correct methods of barrier use and discussed answers to commonly asked questions.
After each session, participants were provided with large 1-month supplies of male and female condoms (sessions 1-3) and N-9 spermicidal products (sessions 2 and 3). Participants were strongly encouraged to use the N-9 products in conjunction with condoms.
Participants in the control condition participated in discussion sessions and/ or viewed a brief stress management educational video, followed by an entertainment film. Intervention and control sessions were identical in length, 120 minutes, and were also held in English, Spanish, and Creole by linguistically matched facilitators.
Outcome Measures
All measures were administered at baseline, 3 months, and 9 months.
Sexual risk behavior was measured using a 60-item scale adapted from the Sexual Risk Behavior Assessment Schedule (SERBAS). 31, 32 The SERBAS-A structured interview measures frequency of sexual behavior and protection used in the past 3 months with primary (most frequent sexual relations) and nonprimary partners. Frequency was identified as all the time or 9 times out of 10, most times or 7 times out of 10, half the time or 5 times out of 10, sometimes or 3 times out of 10, or never. The measure identified the percentage of women sexually active, number of sexual partners, and percentage of women never using condoms (male and/or female combined).
Barrier acceptability was measured with an adaptation of the Barrier Questionnaire. 33 Participants rated current and previous use of, and willingness to use, sexual barriers using a Likert-type scale (with use identified as never used, like very much, like somewhat, neutral, dislike somewhat, strongly dislike; willingness to use identified as not at all willing to use, slightly willing, moderately willing, very willing). Stem prompts were adapted to willingness "to use" products. The measure identified the percentage of women (1) currently using barriers, (2) having previously used spermicides, (3) rating acceptability after use (combined "liked very much" + "liked somewhat," combined "disliked somewhat" + "disliked very much"), and (4) willingness to use (combined "moderately willing" + "very willing to use," combined "not at all willing" + "slightly willing to use").
Gynecological/Sexually Transmitted Disease Assessment
The gynecological assessment was derived from the gynecological examination protocol for phase II microbicide testing recommended by the International Working Group on Vaginal Microbicides, 34 and included 10 domains of vaginal abnormality and previous STD history. The assessment identified the percentage of intervention participants with vaginal lesions, irritation or other contraindications (e.g., discharge, burning, itching) for the use of N-9 spermicides, and STDs. Participants were tested for STDs (chlamydia, gonorrhea, and trichomoniasis) using biological specimens.
Statistical Analyses
This study used a repeated-measures design with condition (sexual barrier intervention, control) as the between-subject factor and time (baseline and 3 and 9 months postintervention) as the within-subject factor. Participants were matched as to age and ethnicity. All comparisons (N = 178) used an α (two tailed) of .05.
RESULTS
Participant Characteristics
The mean age of sample participants (N = 178) was 36 years; most women (81%) were unemployed. The majority (52%) were African American; 18% were Hispanic, 15% were from the Caribbean, 10% were Caucasian, and 5% were of other ethnic backgrounds, including Native American and Pacific Islander. There were 68% who reported having completed the 12th grade, and 21% lived with their partner or spouse. Half had previous histories of drug (50%) and/or alcohol dependence (29%). There were no significant differences in education or employment status between intervention and control condition participants.
Baseline
Most women were sexually active and often practiced unprotected sex; there were no significant differences between conditions. Of all participants, 68% (121) had been sexually active in the last 3 months, 9% (16) with two or more sexual partners. Of those sexually active, 33% (59) reported never using condoms. Almost half of the intervention condition (43%) had a history of one or more STDs; the baseline frequency of STDs was 0%. Of those in the intervention condition, 28% (25) were identified as having abnormal vaginal presentations and were referred for treatment prior to N-9 use.
Previous Use and Willingness to Use at Baseline
One third of all participants (32%) had previously tried using chemical sexual barriers ( Table 1 ). The greatest baseline differences between ethnic groups were found between Haitian women and other ethnic groups (Table 2) .
Three Months Postintervention
At 3 months postintervention, both groups increased their percentage of protected sex acts using a male condom (intervention 40%, P < .001; control 34%, P < .01) when compounded with baseline. Use of N-9 spermicides was significantly higher among women in the intervention condition (χ 2 = 5.04, P < .05; baseline 22%, 3 months postintervention 51%), while male condom use did not diminish. Trial basis use (percentage of women who tried product) of vaginal contraceptive film was significantly higher in the intervention condition (40%) than the control condition (11%; χ 2 = 7.47, P < .05. Women in the control group did not increase trial basis use or willingness to use with regard to N-9 spermicides or female condoms.
Acceptability ratings did not change in either intervention or control conditions (Table 3 ). Willingness to use products with specific characteristics increased from baseline in the intervention condition (timing of product use, c2 = 5.49, P < .05; baseline = moderately to very willing to wait 20 minutes before having sex, 27%, 3 months, 40%, 9 months, 46%) ( Table 4 ). Willingness to use wet products decreased in the intervention condition (χ 2 = 12.78, P < .05; baseline 35%, 3 months 31%). Willingness to use a product without a partner's knowledge increased in the intervention condition over time, while the control condition decreased (moderately to very willing, χ 2 = 16.17, P < .001; baseline, intervention 44%, control 48%, χ 2 = 8.76, P < .01; 3 months postintervention 54%, control 42%). Trial Use, Nine Months Postintervention, Intervention Versus Control At 9 months postintervention, trial basis use of N-9 spermicides (presented in Table  3 ) was significantly higher by participants in the intervention group than by those in the control group (suppositories, χ 2 = 11.73, P < .05; intervention 83%, control 9%; film, χ 2 = 8.25, P < .05; intervention 55%, control 0%), with no change in male condom use. Willingness to use products without partner knowledge increased in the intervention condition (moderately to very willing to use, χ 2 = 7.64, P < .01; baseline 44%, 9 months postintervention 62%). Participant ratings of products following exposure did not change across time in either intervention or control condition (Table 4) .
DISCUSSION
Overall response to this intervention was favorable. We found trial basis use of N-9 spermicides increased for those participating in the sexual barrier intervention without resulting in a decrease in condom use. These results support existing behavioral intervention research involving sexual education, including sexual negotiation skills, 35 female-controlled methods, 12, 36, 37 and hierarchical counseling. 10, 11, 38 Anecdotal reports during the intervention indicated increased awareness of the importance of safer sex in their sexual relationships following the intervention, and additional condoms and N-9 spermicides were generally requested at the final session.
Although trial basis use of N-9 spermicides did not result in a more favorable evaluation of specific products, participants in the intervention increased their will- ingness to use products with characteristics common to N-9 spermicides. The increasing trend noted in the evaluations of trial basis use suggests that results may be limited by the number of women using specific products. As in previous research, participants increased their use of chemical barrier products. 39, 40 These results suggest expressed willingness to use specific barrier products may not be associated with participants' product ratings.
Results demonstrate that ethnic preferences and exposure must be considered in the marketing and dissemination of microbicides. The necessity for an effective and acceptable vaginal chemical barrier method has highlighted the relative lack of information on acceptability among diverse populations. Product acceptability differed among ethnicities along several dimensions, including delivery systems and product characteristics. These diverse preferences can inform the development of microbicidal products.
Finally, although participants were not supplied with additional products after the completion of the intervention, results suggest that use of female-controlled products continued to increase through 9 months postintervention, as did the acceptability of products that can be used without partner knowledge. Increasing acceptability may have been due to ready access to N-9 spermicides in the community or continued, rather than trial basis, use of products previously supplied. The primary limitation of this study was its small sample size, which was com- 
Percentage of intervention condition participants willing to
Percentage of control condition use in future participants willing to use in future Baseline 3 months 9 months Baseline 3 months 9 months (N = 89) (n = 36) (n = 11) (n = 89) (n = 35) (n = 13)
Male condoms  78  80  77  94  90  91  Female condoms  47  40  46  52  56  64  Gels  44  51  62  34  31  37  Suppositories  27  37  39  28  22  18  Films  27  43  54  18  25  27 pounded by several additional factors. Approximately one third of those in the study were not currently sexually active, and one fifth of intervention participants were temporarily restricted from N-9 use due to vaginal abnormalities, common in HIV-positive women. 2 Both factors served to reduce the number of women who used N-9 spermicidal products. In addition, the temporary exclusion of women dependent on substance use may limit the generalizability of the study results given the frequency of HIV-positive women with a history of substance abuse. The use of professional facilitators rather than peer counselors may also limit the generalizability of the study to other settings or populations. Finally, results suggest the expressed willingness to use products and the exposure to products influence actual use; however, sample size restricted predictive analyses relating willingness to use and actual use and exposure to and actual use of N-9 spermicides.
Prevention of HIV sexual transmission does not occur in a vacuum. 41, 42 For women whose partners refuse to use condoms, over-the-counter microbicidal sexual barriers are long overdue and clearly represent an acceptable alternative method of protection. Female-controlled methods of protection allow HIV-positive women to limit transmission to others while ensuring their own protection, an idea whose time has finally come.
